Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2384
  • Joined

  • Last visited

Reputation

2880 Surly 10%

2 Followers

About Harrison Stafford

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. We’re going to find out how much patience Crane has. I wouldn’t be surprised to see a managerial change at the All-Star break if things don’t improve OR look for a player dump in exchange for minor leaguers on the rise. Rome fell, I guess it happens to baseball teams as well.
  2. Oh, yeah? Well, when you’re floating down the gutter and I’m a gazllionaire, I’ll buy you a bottle of wine. You know, it doesn’t hurt to insert a word of caution. These are stonks, and as such, they are high risk and high reward. It’s like Babe Ruth at the plate.. You either strike out or hit a home run. Holding 27,800 shares at an avg cost of $9.77. I’m looking for a shot into the deep centerfield seats.
  3. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-positive-overall-survival-results-anktiva. So, this week, ImmunityBio (IBRX) got approval for their bladder cancer, drug, Anktiva This will go up against Merck’s drug, Keytruda, but Anktiva will become the standard of care for the bladder cancer indication as their results were much better than Merck’s. Today, IBRX announced that Anktiva in conjunction with Keytruda could almost double the survival rate in the standard of care for patients with >lung cancer<. Even the lung cancer patients getting Keytruda and seeing a benefit will eventually relapse. Adding Anktiva to the equation causes the checkpoint inhibitor to resume function. This may exist for several other checkpoint inhibitors and represents a rescue therapy for those with failing checkpoint inhibitor treatments and disease progression in a variety of solid tumors. To that end, IBRX also has a study in phase 2 treating pancreatic cancer with Anktiva in combination with other drugs (now, that Anktiva is FDA approved, label expansion based on second and third line trials can allow other applications). ImmunityBio has a meeting scheduled with the FDA in June to discuss the path to a registration filing of Anktiva plus Keytruda for people (previously getting only Keytruda) whose lung cancer did not respond to checkpoint therapy. ImmunityBio also gets $100 million in nondilutive cash as an infusion with Anktiva’s approval bringing their cash on hand to approximately $240 million for the launch of Anktiva as a treatment for bladder cancer. IBRX will need to build their distribution network from the ground floor as this is their first FDA approved drug, but that’s going to happen. Keytruda sold almost $7 billion in the last quarter as a treatment for various cancers. Do your own DD, but IBRX appears to have limited downside and enormous upside. *Because of the passing of my mother-in-law, I hadn’t planned on visiting Surly today, but the lung cancer treatment with Anktiva is huge and if you’re invested in IBRX or are considering investing in IBRX, you needed to know whazzup.
  4. That’s an insult to all the donkey ballz in the world.
  5. So, our SP tonight has an ERA of 11.57 and the Cubs SP has an ERA of 1.80. No es bueno.
  6. Yeah, it blows. I beat myself up on a daily basis and am way beyond ready for UUUU, RVPH, IBRX (and EOSE, GERN & AMYZF) to be awash in a sea of upticks. I feel like crap as people on this board may have bought and sold these stocks at a loss or are sitting on paper losses (like yours truly). However, the reasons for taking positions in these equities haven’t changed. The timeline for the payoff on a few them has moved in the wrong direction, but the story’s still good. Would post a synopsis of what I see as reasons to buy or hold UUUU, RVPH, IBRX, EOSE, GERN, & ANYZF, but that’s going to have wait for a few days. My wife’s mom passed away this morning and my focus is elsewhere than the bottom line.
  7. Trev Alberts fired 18 employees in the Texas A&M athletic department today. Among those released were Justin Moore, executive deputy athletics director and chief operating officer, as well as Chris Park, deputy athletics director for external relations and business development, and Tyler Pigg according to a source with knowledge of the situation No comment by Trev. This is what happens when you have to pay someone $60,000,000 to not work there.
  8. Anktiva will be available in US mid-May. The big question is does immunityBio remain an unencumbered asset or choose to partner? The company has lots of options on the table. ImmunityBio will have a conference call & webcast this Friday, April 26, at 10AM CDT. We should get some answers.
  9. Patrick Soon-Shiong, a partial owner of the Los Angeles Lakers, said Anktiva represents the first validation of what he called the “triangle offense” of an immune response. (Pier Marco Tacca/Getty Images) After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. approval in the cancer immunotherapy Anktiva. Anktiva, which is an interleukin-15 superagonist, is now cleared by the FDA alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), ImmunityBio said Monday. The drug will now compete with Merck & Co.’s PD-1 inhibitor Keytruda and Ferring Pharmaceuticals’ gene therapy Adstiladrin in the same NMIBC CIS setting regardless of the presence of papillary tumors. Both Anktiva and Adstiladrin are administered directly into the bladder, while Keytruda comes as an intravenous therapy.
  10. IBRX is heavily shorted, so if it pops enough, we might get a nice squeeze. There is also the possibility when the PR is released manana that a partnership with Big Pharma is announced. There’s also the possibility that the company sells some stock to raise money on a rally. Short term, who the hell knows? Long term, ImmunityBio has a serious pipeline and is just getting started.. @Hefeweizen This should be a nice long ride (that’s what she said).
  11. I would add that UUUU has no debt, $1.57/sh in cash, actually, has positive earnings, and is investing to grow. I like all that.
  12. These ying yangs (UUUU) are doing the opposite of unlocking shareholder value in the short term and I’m as unhappy as anyone else with that. Having said that, UUUU is working to develop a supply chain of monazite to make rare earths and today’s announced purchase of Base Resources is to establish more rare earth supply. UUUU is targeting 1000 tons of neodymium and praesodyium production at their plant. This is a big deal because our country does not want to have to rely on China for these rare earths. Indeed, UUUU is working to see if the US government will help them pay for some of this under our government’s critical materials programs. In regards to uranium, UUUU has restarted their uranium mines and it takes a bit for those costs to turn into earnings. I don’t blame you if you want to jettison the stock, but I’m continuing to hold it with hopes of a large payoff down the line.
  13. Thus far, the Astros look rather disinterested….an old team spiraling down.
Ă—
Ă—
  • Create New...